


Edited by
H. U. Blaser and E. Schmidt

 WILEY-VCH

Asymmetric Catalysis on Industrial Scale

Challenges, Approaches and Solutions




Asymmetric Catalysis on Industrial Scale

Challenges, Approaches and Solutions

Edited by

H. U. Blaser, E. Schmidt



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Editors

Dr. Hans-Ulrich Blaser

Solvias AG
P.O. Box
CH-4002 Basel
Switzerland
hans-ulrich.blaser@solvias.com

Dr. Elke Schmidt

Syngenta Crop Protection AG
CH-4058 Basel
Switzerland
elke.schmidt@syngenta.com

■ This book was carefully produced. Nevertheless, editors, authors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published

by Die Deutsche Bibliothek

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>

© 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany
Printed on acid-free paper

Composition K+V Fotosatz GmbH, Beerfelden

Printing betz-druck GmbH, Darmstadt

Bookbinding J. Schäffer GmbH & Co. KG, Grünstadt

ISBN 3-527-30631-5

H. U. Blaser, E. Schmidt (Eds.)

Asymmetric Catalysis on Industrial Scale

Further Reading from Wiley-VCH

Aehle, W.

Enzymes in Industry, 2. Ed.

2003. ISBN 3-527-29592-5

Weissermel, K., Arpe H.-J.

Industrial Organic Chemistry, 4. Ed.

2003. ISBN 3-527-30578-5

Barnfield, P.

Research & Development Management in the Chemical and Pharmaceutical Industry, 2. Ed.

2003. ISBN 3-527-30667-6

Cornils, B., Herrmann, W. A.

Applied Homogeneous Catalysis with Organometallic Compounds, 3 Vols., 2. Ed.

2002. ISBN 3-527-30434-7

List of Contributors

D. AGER
DSM Pharmaceuticals Inc., 5900 NW
Greenville Blvd.
Greenville, NC 27834
USA

L. ANZALONE
Johnson & Johnson
Pharmaceutical Research
& Development, LLC
Spring House, PA 19477
USA

L. AOUNI
Rhodia, Centre de Recherches de Lyon
85 Avenue des Frères Perret
F-69192 St. Fons Cedex
France

T. BAYER
Siemens AG
Industriepark Höchst, G 811
D-65926 Frankfurt am Main
Germany

R. BIRK
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
Postfach
CH-4070 Basel
Switzerland

J. BLACKER
Avecia Process Technology
Leeds Road, P.O. Box 521
Huddersfield, HD2 5AG
UK

H.-U. BLASER
Solvias AG
P.O. Box
CH-4002 Basel
Switzerland

W. BRIEDEN
Lonza AG
Process R&D
CH-3930 Visp
Switzerland

J. C. CAILLE
PPG-Sipsy, Sipsy Chimie Fine
Z.I. la Croix Cadeau B.P. 79
F-49242 Avrillé Cedex
France

C. J. COBLEY
Dowpharma
Chirotech Technology Ltd
A Subsidiary of
The Dow Chemical Company
Unit 321 Cambridge Science Park
Milton Road
Cambridge CB4 0WG
UK

E. DELANEY
Bristol-Myers Squibb
Process R&D
Pharmaceutical Institute
P.O. Box 191
New Brunswick, NJ 08903
USA

S. DOSWALD
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
Postfach
CH-4070 Basel
Switzerland

K. DRAUZ
Degussa AG
Fine Chemicals
Rodenbacher Chaussee 4
D-63457 Hanau-Wolfgang
Germany

M. EISSEN
Laboratory of Chemical Engineering
Swiss Federal Institute of Technology
Zürich
CH-8093 Zürich
Switzerland

H. ESTERMANN
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
Postfach
CH-4070 Basel
Switzerland

P.F. FAUQUET
Novartis Pharma AG
Klybeckstrasse 141
CH-4057 Basel
Switzerland

H.J. FEDERSEL
Astra Zeneca
Process R&D
S-15185 Södertälje
Sweden

R. FUCHS
Lonza AG
Process R&D
CH-3930 Visp
Switzerland

C.K. GOVINDAN
PPG-Sipsy, Sipsy Chimie Fine
Z.I. la Croix Cadeau B.P. 79
F-49242 Avrillé Cedex
France

H. GRÖGER
Degussa AG
Project House Biotechnology
Rodenbacher Chaussee 4
D-63457 Hanau-Wolfgang
Germany

R. HANREICH
Syngenta Crop Protection
Münchwilen AG
CH-4333 Münchwilen
Switzerland

K.E. HEMBERGER
Rhodia ChiRex
56 Roland Street
Boston, MA 02129
USA

K. HUNGERBÜHLER
Laboratory of Chemical Engineering
Swiss Federal Institute of Technology
Zürich
CH-8093 Zürich
Switzerland

S. JASMIN
Rhodia ChiRex
56 Roland Street
Boston, MA 02129
USA

N.B. JOHNSON
Dowpharma
Chiretech Technology Ltd
A Subsidiary of
The Dow Chemical Company
Unit 321 Cambridge Science Park
Milton Road
Cambridge CB4 0WG
UK

H. KABIR
Rhodia, Centre de Recherches de Lyon
85 Avenue des Frères Perret
F-69192 St. Fons Cedex
France

N. KASAI
Osaka Prefecture University
Laboratory of Food Chemistry
Division of Applied Biological
Chemistry
Graduate School of Agriculture
& Biological Sciences
Gakuen-cho, Sakai, Osaka 599-8531
Japan

A. KIENER
Lonza AG
Department of Biotechnology
CH-3930 Visp
Switzerland

W.S. KNOWLES
661 East Monroe Avenue
St. Louis, MO63122
USA

E. KUPFER
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
Postfach
CH-4070 Basel
Switzerland

J. LALONDE
PPG-Sipsy, Sipsy Chimie Fine
Z.I. la Croix Cadeau B.P. 79
F-49242 Avrillé Cedex
France

S.A. LANEMANN
Albany Molecular Research Inc
601 East Kensington Road
Mount Prospect IL 60056
USA

J.F. LARROW
Rhodia ChiRex
56 Roland Street
Boston, MA 02129
USA

M. LARSSON
Astra Zeneca
Process R&D
S-15185 Södertälje
Sweden

I. LE-FUR
Rhodia, Centre de Recherches de Lyon
85 Avenue des Frères Perret
F-69192 St. Fons Cedex
France

I.C. LENNON
Dowpharma
Chiretech Technology Ltd
A Subsidiary of
The Dow Chemical Company
Unit 321 Cambridge Science Park
Milton Road
Cambridge CB4 0WG
UK

J. MARTIN
Avecia Process Technology
Leeds Road, P.O. Box 521
Huddersfield, HD2 5AG
UK

A. MATSUYAMA
Tsukuba Research Center
Daicel Chemical Industries Ltd
Tsukuba, Ibaraki
Japan

R. McCAGUE
Dowpharma
Chiretech Technology Ltd
A Subsidiary of
The Dow Chemical Company
Unit 321 Cambridge Science Park
Milton Road
Cambridge CB4 0WG
UK

J. F. McGARRITY
Lonza AG
Process R&D
CH-3930 Visp
Switzerland

K. McGEE
Pfizer Inc.
Global Research and Development
La Jolla, San Diego, California
USA

H. P. MEITLER
Lonza AG
Process R&D
CH-3930 Visp
Switzerland

P. MOREL
Rhodia, Centre de Recherches de Lyon
85 Avenue des Frères Perret
F-69192 St. Fons Cedex
France

T. NETSCHER
Roche Vitamins Ltd
Research and Development
Bldg 214/27
CH-4070 Basel
Switzerland

J. PESTI
Bristol-Myers Squibb
Process R&D
Pharmaceutical Research Institute
B.O. Box
Princeton, NJ 08543-4000
USA

P. POECHLAUER
DSM Fine Chemicals Austria
R&D Center
Linz
Austria

J. S. PRASAD
Bristol-Myers Squibb
Process R&D
Pharmaceutical Institute
P.O. Box 191
New Brunswick, NJ 08903
USA

J. A. RAMSDEN
Dowpharma
Chiretech Technology Ltd
A Subsidiary of
The Dow Chemical Company
Unit 321 Cambridge Science Park
Milton Road
Cambridge CB4 0WG
UK

K. T. ROBINS
Lonza AG
Department of Biotechnology
CH-3930 Visp
Switzerland

M. SCALONE
F. Hoffmann-La Roche Ltd
Pharmaceuticals Division
Process Research & Catalysis
CH-4070 Basel
Switzerland

T. SCHLAMA
Rhodia, Centre de Recherches de Lyon
85 Avenue des Frères Perret
F-69192 St. Fons Cedex
France

R. SCHMID
F. Hoffmann-La Roche Ltd
Pharmaceuticals Division
Process Research & Catalysis
CH-4070 Basel
Switzerland

B. SCHMIDT
Lonza AG
Process R&D
CH-3930 Visp
Switzerland

E. SCHMIDT
Syngenta Crop Protection AG
CH-4058 Basel
Switzerland

H.-D. SCHNEIDER
Syngenta Crop Protection
Münchwilen AG
CH-4333 Münchwilen
Switzerland

G. SEDELMEIER
Novartis Pharma AG
Klybeckstrasse 141
CH-4057 Basel
Switzerland

R. SELKE
Leibniz-Institut für Organische Kata-
lyse an der Universität Rostock e.V.
Buchbinderstraße 5–6
D-18055 Rostock
Germany

N.M. SHAW
Lonza AG
Department of Biotechnology
CH-3930 Visp
Switzerland

A.K. SINGH
Bristol-Myers Squibb
Process R&D
Pharmaceutical Institute
P.O. Box 191
New Brunswick, NJ 08903
USA

W. SKRANC
DSM Fine Chemicals Austria
R&D Center
Linz
Austria

M. SOUKUP
Efeuweg 5
CH-4103 Bottmingen
Switzerland

F. SPINDLER
Solvias AG
P.O. Box
CH-4002 Basel
Switzerland

F. STÄBLER
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
Postfach
CH-4070 Basel
Switzerland

B. STEINACHER
Syngenta Crop Protection
Münchwilen AG
CH-4333 Münchwilen
Switzerland

M. STUDER
Solvias AG
P.O. Box
CH-4002 Basel
Switzerland

T. SUZUKI
 Research Laboratories
 of DAISO Co. Ltd
 9 Otakasu-Cho, Amagasaki
 Hyogo 660-0842
 Japan

J. TAO
 Pfizer Inc.
 Global Research and Development
 La Jolla, San Diego, California
 USA

R. S. TOPGI
 Pfizer Inc.
 Research and Development
 Chemical Sciences
 Skokie, IL 60077
 USA

T. WEISBROD
 European Patent Office
 Bayerstr. 35
 D-80335 München
 Germany

O. WERBITZKY
 Lonza AG
 Process R&D
 CH-3930 Visp
 Switzerland

B. WIRZ
 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse 124
 Postfach
 CH-4070 Basel
 Switzerland

R. WOHLGEMUTH

Fluka Group
 Industriestrasse 25
 CH-9470 Buchs
 Switzerland

W. WOSTL
 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse 124
 Postfach
 CH-4070 Basel
 Switzerland

M. WUBBOLTS
 DSM Fine Chemicals
 P.O. Box 43
 6130 AA Sittard
 The Netherlands

Y. YAO
 PPG-Sipsy, Sipsy Chimie Fine
 Z.I. la Croix Cadeau B.P. 79
 F-49242 Avrillé Cedex
 France

H. YAMAMOTO
 Tsukuba Research Center
 Daicel Chemical Industries Ltd
 Tsukuba, Ibaraki
 Japan

A. ZANOTTI-GEROSA
 Dowpharma
 Chirotech Technology Ltd
 A Subsidiary of
 The Dow Chemical Company
 Unit 321 Cambridge Science Park
 Milton Road
 Cambridge CB4 0WG
 UK

Contents

List of Contributors *XXI*

Introduction *1*

Hans-Ulrich Blaser and Elke Schmidt

1	Background and Motivation	1
2	Goals and Concept	1
3	Our (the Editors) Assessment of the Resulting Monograph	2
4	The Organization of the Book (Types of Intermediates – Catalysts – Situations)	3
4.1	Category: New Processes for Existing Active Compounds	5
4.2	Category II: New Catalysts and/or Processes for Important Building Blocks	5
4.3	Category III: Adaptation of Existing Catalysts for Important Building Blocks	6
4.4	Category IV: Processes for New Chemical Entities (NCE)	6
5	Missing Processes	6
6	Some Important Messages	9
6.1	Transformations and Catalyst Types	10
6.2	Scale, Development Stage	13
6.3	Synthesis Planning and Time Lines	13
6.4	Major Technical Problems	14
6.5	Technology and Patents	14
7	Final Comments and Conclusions	15
8	Glossary	16
9	References	18

I	New Processes for Existing Active Compounds	21
1	Asymmetric Hydrogenations – The Monsanto L-Dopa Process	23
	<i>William S. Knowles</i>	
1.1	The Development of Chiral Phosphane Ligands	23
1.2	Synthesis and Properties of the Phosphanes	31
1.3	Mechanism of the Asymmetric Catalysis	35
1.4	Concluding Comments	37
1.5	Acknowledgements	38
1.6	References	38
2	The Other L-Dopa Process	39
	<i>Rüdiger Selke</i>	
2.1	Introduction	39
2.2	Choice of the Substrate	42
2.3	The Catalyst	44
2.4	Improving the Hydrogenation Reaction	45
2.5	Effect of Solvent and Anions	46
2.6	Immobilization of the Catalyst	49
2.7	Production Process	49
2.8	Acknowledgements	52
2.9	References	52
3	The Chiral Switch of Metolachlor: The Development of a Large-Scale Enantioselective Catalytic Process	55
	<i>Hans-Ulrich Blaser, Reinhard Hanreich, Hans-Dieter Schneider, Felix Spindler, and Beat Steinacher</i>	
3.1	Introduction and Problem Statement	55
3.2	Route Selection	56
3.2.1	Enamide Hydrogenation	56
3.2.2	Nucleophilic Substitution of an (<i>R</i>)-Methoxyisopropanol Derivative	57
3.2.3	Hydrogenation of MEA Imine	57
3.2.4	Catalytic Alkylation with Racemic Methoxyisopropanol	58
3.2.5	Assessment and Screening of the Proposed Routes	58
3.3	Imine Hydrogenation: Laboratory Process	59
3.3.1	Finding the Right Metal-Ligand Combination	59
3.3.1.1	Screening of Rh-Diphosphine Complexes	59
3.3.1.2	Screening of Ir-Diphosphine Complexes	60
3.3.1.3	Synthesis and Screening of a New Ligand Class	60
3.3.2	Optimization of Reaction Medium and Conditions	61
3.3.3	Ligand Fine Tuning	61
3.4	Imine Hydrogenation: Technical Process	62
3.4.1	Strategy for Process Development	62
3.4.2	The Production of the MEA Imine at the Required Quality	62
3.4.3	Scale-up of the Ligand Synthesis	63

3.4.4	Fine Optimization of the Ir-Catalyst Formulation	65
3.4.5	Choice of Reactor Technology	65
3.4.6	Scale-Up to the Production Autoclave	66
3.4.7	Work-up, Separation of the Catalyst from the Product	67
3.5	Summary and Conclusions	68
3.6	Acknowledgements	69
3.7	References	69
4	Enantioselective Hydrogenation:	
	Towards a Large-Scale Total Synthesis of (R,R,R)-α-Tocopherol	71
	<i>Thomas Netscher, Michelangelo Scalone, and Rudolf Schmid</i>	
4.1	Introduction: Vitamin E as the Target	71
4.2	Routes to (2R,4'-R,8'R)- α -Tocopherol by Total Synthesis	74
4.3	Synthesis of Prochiral Allylic Alcohols	76
4.4	Asymmetric Hydrogenation of Prochiral Allylic Alcohols	78
4.5	Synthesis of the Diphosphane Ligands	81
4.6	Procedures for Stereochemical Analysis	84
4.7	Concluding Remarks	86
4.8	Acknowledgements	87
4.9	References	87
5	Comparison of Four Technical Syntheses	
	of Ethyl (R)-2-Hydroxy-4-Phenylbutyrate	91
	<i>Hans-Ulrich Blaser, Marco Eissen, Pierre F. Fauquex, Konrad Hungerbühler, Elke Schmidt, Gottfried Sedelmeier, and Martin Studer</i>	
5.1	Introduction	91
5.2	Synthetic Pathways to HPB Ester	92
5.2.1	Route A: Synthesis and Enantioselective Reduction of Keto Acid 3 with Immobilized <i>Proteus vulgaris</i> Followed by Esterification	94
5.2.2	Route B: Enantioselective Reduction of 3 with D-LDH in a Membrane Reactor	94
5.2.3	Route C: Synthesis and Enantioselective Hydrogenation of Keto Ester 5	95
5.2.4	Route D: Synthesis and Enantioselective Hydrogenation of Diketo Ester 6, Followed by Hydrogenolysis	95
5.3	Comparison of Routes A–D with Respect to Mass Consumption, Environmental, Health and Safety Aspects	96
5.3.1	Definitions	96
5.3.2	Overall Material Masses Consumed and Produced for Routes A–D	97
5.3.3	Mass Consumption of the Reduction Systems A–D	98
5.3.4	Problematic Chemicals: Environmental, Health and Safety Aspects (EHS)	99
5.3.4.1	Safety Aspects	99
5.3.4.2	Health/Toxicology	100

5.3.4.3	Environment	100
5.4	Overall Comparison of Routes A–D and General Conclusions	100
5.4.1	Conclusions for the Reduction Steps	100
5.4.2	Conclusions for the Overall Syntheses	101
5.5	References	103
6	Biocatalytic Approaches for the Large-Scale Production of Asymmetric Synthons	105
	<i>Nicholas M. Shaw, Karen T. Robins, and Andreas Kiener</i>	
6.1	Introduction	105
6.2	Asymmetric Biocatalysis	106
6.2.1	L-Carnitine	106
6.2.2	Asymmetric Reduction: (R)-Ethyl-4,4,4-trifluorohydroxybutanoate	107
6.3	Resolution of Racemic Mixtures	108
6.3.1	(R)- and (S)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionic Acid	108
6.3.2	(S)-2,2-Dimethylcyclopropane Carboxamide	111
6.3.3	CBZ-D-proline [(R)-N-CBZ-proline]	113
6.3.4	(1R,4S)-1-Amino-4-hydroxymethyl-cyclopent-2-ene	114
6.4	Summary	114
6.5	References	115
7	7-Aminocephalosporanic Acid – Chemical Versus Enzymatic Production Process	117
	<i>Thomas Bayer</i>	
7.1	Introduction	117
7.2	Synthesis of 7-ACA	119
7.2.1	The Chemical 7-ACA Route	120
7.2.2	Single Step Biocatalytic 7-ACA Synthesis	121
7.2.3	Two-step Biocatalytic 7-ACA Synthesis	122
7.2.4	Two-Step Biocatalytic Process	125
7.2.4.1	Oxidation	126
7.2.4.2	Deacylation	127
7.3	Comparison of Chemical and Two-Step Biocatalytic 7-ACA Process	127
7.4	Conclusion	129
7.4	References	130
8	Methods for the Enantioselective Biocatalytic Production of L-Amino Acids on an Industrial Scale	131
	<i>Harald Gröger and Karlheinz Drauz</i>	
8.1	Introduction	131
8.2	L-Amino Acids via Enzymatic Resolutions	133
8.2.1	Processes Using L-Amino Acylases	133
8.2.2	Processes Using L-Amidases	135
8.2.3	Processes Using L-Hydantoinases	137

8.2.4	Processes via Lactam Hydrolysis	139
8.3	L-Amino Acids via Asymmetric Biocatalysis	140
8.3.1	Processes via Reductive Amination	140
8.3.2	Processes via Transamination	142
8.3.3	Processes via Addition of Ammonia to α,β -Unsaturated Acids	143
8.4	Conclusion	145
8.5	References	145
II	New Catalysts for Existing Active Compounds	149
1	The Large-Scale Biocatalytic Synthesis of Enantiopure Cyanohydrins	151
	<i>Peter Poechlauer, Wolfgang Skranc, and Marcel Wubbolts</i>	
1.1	Introduction	151
1.2	Chiral Cyanohydrins as Building Blocks in the Synthesis of Fine Chemicals	151
1.3	Synthesis of Enantiopure Cyanohydrins	152
1.3.1	General Methods	152
1.3.1.1	Sources of HCN	152
1.3.1.2	The Sources of Chirality of Cyanohydrins	153
1.3.2	Syntheses via Chiral Metal Catalysts	154
1.3.3	Cyanohydrin Synthesis via Cyclic Dipeptides	154
1.3.4	The Cyanohydrin Synthesis via Lipases	156
1.3.5	Synthesis of Chiral Cyanohydrins Using Hydroxy Nitrile Lyases (HNLs)	157
1.4	Large-Scale Cyanohydrin Production	158
1.4.1	General Considerations	158
1.4.2	Scale-up of HNL-Catalyzed Cyanohydrin Formation	159
1.5	Examples of Large-Scale Production of Cyanohydrins	161
1.5.1	Production of (<i>S</i>)-3-Phenoxybenzaldehyde Cyanohydrin (SCMB)	162
1.5.2	Production of (<i>R</i>)- and (<i>S</i>)-Mandelic Acid Derivatives	163
1.6	Summary	163
1.7	References	163
2	Industrialization Studies of the Jacobsen Hydrolytic Kinetic Resolution of Epichlorohydrin	165
	<i>Larbi Aouni, Karl E. Hemberger, Serge Jasmin, Hocine Kabir, Jay F. Larrow, Isidore Le-Fur, Philippe Morel, and Thierry Schlama</i>	
2.1	Background	165
2.2	The HKR Catalyst	166
2.2.1	Preparation and Isolation of Active Catalyst	167
2.2.2	Activation Step Characterization	169
2.2.2.1	Quantitative Analysis of Co(II) and Co(III) Species	169
2.2.2.2	Kinetic Limitation of the Co(II) to Co(III) Oxidation Reaction	169
2.2.3	Scale-up Considerations for the (Salen)-Co(III)-OAc Process	174
2.3	Kinetic Modelling and Simulation of the HKR Reaction	176